The Economics Of Orphan Blockbuster Drug Development

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Drug Development

Background:

• The Medicare Drug Price Negotiation Program offers exemptions or delays for drugs with orphan indications.
• The necessity of these protections for sustaining orphan drug development remains uncertain.

Purpose of the Study:

• To evaluate the necessity of orphan drug protections in Medicare negotiations.
• To compare clinical trial costs, worldwide revenues, and time to cost recovery for drugs based on their orphan status and exemption/delay from negotiation.

Main Methods:

• Analysis of 167 drugs projected to exceed $200 million in annual Medicare spending.
• Classification of drugs by orphan status: exempt under IRA, exempt under OBBBA, delayed under OBBBA, and non-orphan/non-qualifying.
• Comparison of clinical trial costs, worldwide revenues, and time to cost recovery.

Main Results:

• 94% of all studied drugs recovered clinical trial costs within ten years of global launch.
• IRA-exempt orphan drugs were younger, had lower trial costs, comparable revenues, and faster cost recovery than non-qualifying drugs.
• OBBBA-exempt and OBBBA-delayed drugs showed no significant difference in cost recovery compared to non-qualifying drugs.

Conclusions:

• Drugs with orphan protections recover development costs comparably or faster than non-qualifying drugs.
• The findings question the need to protect blockbuster orphan drugs from Medicare price negotiation.
• Current orphan drug protections may not be essential for recouping development costs.